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Key Points for Decision Makers 
 
• The most relevant comparator to dabrafenib in clinical practice today is vemurafenib. No 
direct evidence comparing these two drugs exists and so an indirect treatment comparison 
(ITC) was conducted. However, the statistical assumptions required for the conduct this ITC 
were not considered to be valid by the Evidence Review Group (ERG).  
• In the ERG’s view, the lack of a robust ITC precluded a credible assessment of the relative 
cost-effectiveness of dabrafenib to vemurafenib. In addition the assessment of the model 
used to compare the cost-effectiveness of dabrafenib to dacarbazine identified additional 
issues which undermined its credibility, most importantly the methods used to project 
overall survival were not based on trial data.  
• The overall costs of treatment with dabrafenib were considered to be similar to the overall 
costs of treatment with vemurafenib. 
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Abstract 
The National Institute for Health and Care Excellence (NICE) invited GlaxoSmithKline, the 
manufacturer of dabrafenib, to submit evidence for the clinical and cost effectiveness of 
dabrafenib for the treatment of unresectable, advanced or metastatic BRAF V600 mutation 
positive melanoma in accordance with the Institute’s Single Technology Appraisal (STA) 
process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool 
was commissioned to act as the Evidence Review Group (ERG). This article summarizes the 
ERG’s review of the evidence submitted by the company and provides a summary of the 
Appraisal Committee’s (AC) final decision in October, 2014. 
 
The clinical evidence for dabrafenib was derived from an ongoing phase III randomized double-
blind placebo-controlled international multicentre clinical trial (BREAK-3) involving 230 patients 
randomized 2:1 to receive either dabrafenib or dacarbazine. A significant improvement in 
median PFS but not OS was reported in the dabrafenib arm compared to dacarbazine. 
Vemurafenib is considered a more appropriate comparator than dacarbazine. The clinical 
evidence for vemurafenib was derived from a completed phase III randomized double-blind 
placebo-controlled international multicentre clinical trial (BRIM-3) involving 675 patients 
randomized 1:1 to receive either vemurafenib or dacarbazine. A significant improvement in 
median PFS and OS was reported in the vemurafenib arm compared to dacarbazine. As there is 
no direct evidence comparing dabrafenib vs vemurafenib, the company presented an indirect 
treatment comparison (ITC) that demonstrated no statistical differences between dabrafenib 
and vemurafenib for PFS or OS. The ERG expressed concerns with the ITC, mainly in relation to 
the validity of the assumptions underpinning the methodology; the ERG concluded this resulted 
in findings which are unlikely to be robust or reliable. 
 
Dabrafenib and vemurafenib are both available to patients treated by the NHS in England via a 
Patient Access Scheme (PAS) in which the costs of the drugs are discounted. Using these 
discounted costs, the incremental cost effectiveness ratios (ICERs) generated by the company 
were £60,980 per quality adjusted life year (QALY) for dabrafenib vs dacarbazine and £11,046 
per QALY gained for dabrafenib vs vemurafenib. The ERG considered the economic model 
structure developed by the company to derive the ICERs to be overly complex and based on 
unsubstantiated assumptions, most importantly in relation to the projection of OS. Applying the 
latest OS data from BREAK-3 to a less complex model structure increased the estimated ICER 
for dabrafenib compared with dacarbazine from £60,980 to £112,727 per QALY gained. Since 
the results from the ITC were considered by the ERG to be neither reliable nor robust, the ERG 
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also considered a cost-effectiveness comparison to be inappropriate due to a lack of 
meaningful or reliable data. 
 
In spite of limitations in the data, the AC took the view that dabrafenib and vemurafenib were 
‘likely’ of similar clinical effectiveness. Since the overall costs of these two drugs were similar, 
the AC recommended the use of dabrafenib in patients with unresectable, advanced or 
metastatic BRAF V600 mutation-positive melanoma. 
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1 Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organization 
responsible for providing national guidance to the NHS in England on a range of clinical and 
public health issues, as well as the appraisal of new health technologies. The NICE Single 
Technology Appraisal (STA) process is specifically designed for the appraisal of a single health 
technology for a single indication, where most of the relevant evidence lies with one company 
[1]. Typically, the process is used for new pharmaceutical products close to launch. The 
evidence for a STA is principally derived from a submission by the company that manufactures 
the technology and is based on a specification developed by NICE. The company’s submission is 
critiqued by members of the independent Evidence Review Group (ERG) who produce a report 
to be considered by a NICE Appraisal Committee (AC). 
 
The AC considers the submissions from the company and the ERG alongside testimony from 
experts, patients and other stakeholders to formulate preliminary guidance or a final 
determination. This article presents a summary of the ERG report for the STA of dabrafenib for 
the treatment of unresectable, advanced or metastatic BRAF V600 mutation positive 
melanoma. 
 
Full details of all relevant appraisal documents (including the appraisal scope, ERG report, 
company and consultee submissions, NICE guidance and comments on each of these) can be 
found on the NICE website [2]. 
 
2 The Decision Problem 
Malignant melanoma is one of the most aggressive forms of skin cancer and is currently the 
fifth most common cancer in the UK with incidence rates on the rise as evidenced by the fact 
that from 1999-2001 there were 11 cases/100,000 population while in the period 2008-11 
there were 17/100,000 population [3]. In the UK in 2010 there were over 12,000 new cases 
diagnosed and over 2,000 deaths [3]. Metastatic disease is seen in about 20 % of patients [4] 
while BRAF V600 mutations are found in around 50 % of melanomas [5]. Although the majority 
of melanomas (80 to 90 %) are diagnosed as local tumours that can be surgically removed, 2 to 
8 % of patients have metastatic disease (Stage III and IV) on initial presentation. [6, 7] Patients 
with Stage III disease have a 5-year survival rate of 40 to 80 %, [8] while those with Stage IV 
disease have a much poorer prognosis with median survival times of only 6 to 18 months. 
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Those with metastasis to the brain have an even poorer prognosis and a life expectancy of only 
3 to 5 months. [9] 
 
Until recently, systemic first-line treatment for patients with unresectable, advanced or 
metastatic BRAF V600 mutation-positive melanoma has been with dacarbazine, a treatment 
known to be of limited effectiveness [10, 11]. In late 2012 NICE approved the use of 
vemurafenib to treat unresectable, advanced or metastatic BRAF V600 mutation-positive 
melanoma [12]. In addition NICE has previously approved ipilimumab for both first and second-
line treatment of any patient regardless of BRAF status [13, 14]. Dabrafenib is an alternative 
BRAF inhibitor to vemurafenib. It has received marketing authorization in Europe as 
monotherapy ‘for the treatment of adult patients with unresectable or metastatic melanoma 
with a BRAF V600 mutation.’ [15]  
 
NICE developed a scope for the assessment of dabrafenib within its licensed indication as 
monotherapy for unresectable or metastatic melanoma in patients with BRAF V600 mutation. 
[15] The NICE scope indicated that the comparator treatments for patients who were treatment 
naïve were dacarbazine and vermurafenib and in patients who had been previously treated 
with dacarbazine (or temozolomide for patients with brain metastasis), ipilimumab or 
vemurafenib. It is worth noting that during the timeframe of this appraisal process, NICE had 
approved ipilimumab for treatment naïve patients as well as for patients after initial treatment 
failure. The specified outcomes to be considered were progression free survival (PFS), overall 
survival (OS), response rate, adverse effects (AEs) and health related quality of life (QoL). The 
scope specified that the cost effectiveness of the treatment should be presented in terms of the 
incremental cost per quality-adjusted life year (QALY) gained using a lifetime horizon that was 
sufficiently long to reflect differences in costs or outcomes between the technologies. Costs 
were to be considered from an NHS and Personal Social Services perspective. No specific 
subgroups of patients and no potential equity or equality issues were identified. 
 
3 Independent Evidence Review Group Report 
The evidence provided by the company comprises an initial submission and the company’s 
response to the ERG’s request for clarification. The ERG report [16] is a critical review of the 
evidence for the clinical and cost effectiveness of the technology. It has the following three 
aims: 
• To assess whether the company’s submitted evidence conforms to the methodological 
guidelines issued by NICE 
 Page 7 of 27 
 
• To assess whether the company’s interpretation and analysis of the evidence are 
appropriate 
• To indicate the presence of other sources of evidence or alternative interpretations of the 
evidence that could help inform the development of NICE guidance  
 
In addition to providing this detailed critique, the ERG modified a number of key assumptions 
and parameters within the company’s economic model to examine the impact of such changes 
on cost effectiveness results.  
 
The primary evidence in the submission [11] was derived from a randomized control trial called 
BREAK-3 [17] which compared dabrafenib to dacarbazine. In order to compare dabrafenib to 
vemurafenib, an indirect treatment comparison (ITC) was required utilising additional evidence 
from BRIM-3, [18] which compared dacarbazine to vemurafenib. Each of these trials addressed 
the use of the drugs in treatment naïve patients. No evidence related to the use in previously 
treated patients was submitted. In addition the ERG used data provided from the company 
including the BREAK-3 clinical study report [19]. Secondary supporting evidence from other 
trials assessing the use of dabarafenib was provided, two RCTs (Phase III BRF113220 [20] trial 
and Phase II Combi-d [21] trial) and two Phase II non-RCTs (BREAK-2 [22] and BREAK-MB [23]). 
However this evidence involved patient populations and comparators that were different to 
those specified in the NICE decision problem and thus precluded their inclusion in any 
quantitative synthesis. 
 
 
3.1 Clinical Evidence 
BREAK-3 [17] was a randomized, open-label, multi-centre (70) phase III trial carried out in 12 
countries (but not the UK) between December 2010 and September 2011. Patients were 
randomized in a 2:1 manner to receive either oral dabrafenib 10 mg twice daily (n=167) or 
intravenous dacarbazine 1000mg/m2 every 3 weeks (n=63). The primary outcome was 
investigator assessed PFS and the initial data cut-off for this outcome was December 2011 with 
a subsequent data-cut for PFS in June 2012. Secondary outcomes relevant to the decision 
problem were OS, overall response rate (ORR) (i.e. complete or partial response on RECIST 
version 1.1), AEs and HRQoL. Follow-up for OS continues with the latest data analysis in 
December 2012. BREAK-3 [17] allowed patients to cross over to dabrafenib treatment if their 
disease progressed. At the time of the final PFS data analysis, 57 % of patients had crossed over 
to receive dabrafenib. In order to consider the potential effect of crossover on OS, the Rank 
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Preserving Structural Failure Time method (RPSFTM) was employed. The median length of 
follow-up for PFS (June 2012) was 10.5 months for dabrafenib and 9.9 months for dacarbazine; 
for OS (December 2012) it was 15.2 and 12.7 months respectively. 
 
BRIM-3 [18] was a randomized, open-label, multi-centre (104) phase III trial carried out in 12 
countries (including the UK) from January to December 2010. Patients were randomized in a 1:1 
manner to receive either oral vemurafenib 240 mg eight times daily (n=337) or intravenous 
dacarbazine 1000mg/m2 every 3 weeks (n=338). Joint primary outcomes were OS and 
investigator assessed PFS. Secondary outcomes relevant to the decision problem were ORR (i.e. 
complete or partial response on RECIST version 1.1), AEs and HRQoL. BRIM-3 [18]  allowed 
patients to cross over to vemurafenib treatment if their disease progressed. At the time of the 
final OS data analysis, 34 % of patients had crossed over to receive vemurafenib. In order to 
consider the potential effect of crossover on OS, OS censored at the time when patients in the 
dacarbazine group crossed over to receive vemurafenib was presented in the published paper 
reporting final OS results [18]. However, in the STA for vemurafenib for locally advanced or 
metastatic BRAF V600 mutation positive malignant melanoma, [12] OS was also adjusted using 
the RPSFTM. The median length of follow-up for both OS and PFS was 12.5 months for the 
vemurafenib arm and 9.5 months for the dacarbazine arm. 
 
Compared to dacarbazine, both trials reported apparent improvements in PFS, OS and ORR 
(Table 1). The improvements in PFS were statistically significant, differences in median PFS 
being 4.2 months for dabrafenib and 5.3 months for vemurafenib. A statistically significant 
improvement in OS of 3.3 months has also been reported for vemurafenib. The reported 
improvement in OS of 2.6 months for dabrafenib is not statistically significant but the data are 
still immature as not all planned events (deaths) have occurred. When OS was adjusted using 
the RPSFTM, a significant improvement was reported for vemurafenib vs dacarbazine but not 
dabrafenib vs dacarbazine.  
 
In order to compare dabrafenib to vemurafenib, the company carried out ITCs for PFS and OS 
using the adjusted ITC methodology described by Bucher [24]. Initially, inputs for the ITC for OS 
were crossover adjusted results (using the RPSFTM) from BRIM-3 [18] (February 2012 data-cut) 
and BREAK-3 [17] (December 2012 data-cut). The results were described by the company as 
showing a trend in favour of dabrafenib over vemurafenib for both PFS and OS but the 
treatment difference was not found to be statistically significant for either outcome. At the 
request of the ERG, the unadjusted OS hazard ratios were input into the ITC instead of the 
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RPSFTM adjusted OS hazard ratios. The unadjusted OS results suggest that dabrafenib and 
vemurafenib may be of equal clinical efficacy. The ITC findings are summarized in Table 2.  
 
Both trials were considered by the company to have low risk of bias.  However several 
differences in the characteristics of the two included trials were identified by the company 
including differences in sample sizes, ratios of randomization and timings of follow-up. It was 
unclear if this would impact on any ITC between the two trials. 
 
Dabrafenib was reported to be associated with a manageable safety profile. Notably, pyrexia 
was more common with dabrafenib than dacarbazine (31 % vs 10 % respectively), although the 
maximum severity of pyrexia in BREAK-3 [17] was Grade 3 (3 % vs 0 respectively). Although 
there are no head-to-head data comparing dabrafenib to vemurafenib, pyrexia was less 
common in the vemurafenib arm in BRIM-3 [25] (16 %, all Grade 1). On the other hand, 
dabrafenib appears to be associated with a lower incidence of certain types of 
hyperproliferative skin toxicities than vemurafenib: in BREAK-3 [17], 6 % of patients reported 
cutaneous SCC/keratoacanthoma (2 % Grade 3 events) compared to 17 % cutaneous SCC (16 % 
Grade 3) and 9 % keratoacanthomas (all Grade 3). Photosensitivity was also less common in the 
dabrafenib arm of BREAK-3 [17] compared to the vemurafenib arm of BRIM-3 [25]: 3 % vs 33 % 
respectively (Grade 3 photosensitivity: 0 vs 3 % respectively). 
 
HRQoL data were only presented for the BREAK-3 trial [17]. Descriptive statistics on EQ-5D 
utility index in the BREAK-3 study were presented by the company; the mean change in EQ-5D 
utility index score from baseline to week 15 was lower in the dabrafenib arm (+0.053) than in 
the dacarbazine arm (+0.128). It was also argued by the company that photosensitivity can have 
a ‘significant effect’ on HRQoL which as noted above was lower in patients treated with 
dabrafenib than those treated with vemurafenib [11]. 
 
3.1.1 Critique of Clinical Evidence and Interpretation 
Both the BREAK-3 [17] and BRIM-3 [18] are of good methodological quality with minimum risk 
of bias. The patient populations appear to largely reflect people who would normally be eligible 
for dabrafenib and vemurafenib outside of the clinical trial setting. However, the ERG did note 
that the characteristics of the patients in the two included trials may not be wholly comparable. 
In respect to age, sex, ethnicity, ECOG performance status and tumour, node, metastases 
staging at screening, the two trials appeared to be very similar but in BRIM-3 [18] a greater 
proportion of patients had lactate dehydrogenase (LDH) levels above the upper limit of the 
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normal range than in BREAK-3 [17] (58 % vs 34 % respectively). As the level of LDH has been 
shown to result in worse PFS and OS, [8, 26] patients in both arms of the BRIM-3 [18] trial might 
be expected to have worse outcomes than those in the BREAK-3 [17] trial. Indeed, it was noted 
that median OS did differ in the dacarbazine arms of the trials, being lower in BRIM-3 [18] (9.7 
months) than BREAK-3 [17] (15.6 months). This may be indicative of differences in the patient 
population and/or differences in subsequent treatment received following disease progression 
in the two trials.  
 
As noted above, 57 % of patients in BREAK-3 [17] crossed over to receive dabrafenib and in 
BRIM-3 [18], 34 % of patients crossed over to receive vemurafenib. In total, 78 % of patients in 
the dacarbazine arm of BREAK-3 [17] received additional treatment on disease progression 
compared to 55 % of patients in the dabrafenib arm. As summarized in Table 3, the most 
common type of treatment received varied by arm. Detailed information on post-progression 
treatment for BRIM-3 [18] has not been published but in a response [27] to the first ACD for the 
vemurafenib STA (vemurafenib for locally advanced or metastatic BRAF V600 mutation positive 
malignant melanoma [12]), the manufacturer of vemurafenib noted second-line use of 
ipilimumab in the dacarbazine arm was 19 % compared to 13 % in the vemurafenib arm.  
 
In relation to the BREAK-3 [17] trial, the ERG is not of the opinion that the RPSFTM is an 
appropriate method of adjustment for crossover for three key reasons. First, survival data from 
the BREAK-3 [17] study are immature; the results are based on an interim analysis with few 
deaths. Second, the company’s RPSFTM analysis assumes that the effect of receiving dabrafenib 
is the same when received on diagnosis (i.e. in the dabrafenib group) as it is on disease 
progression (i.e. in dacarbazine crossover patients). The ERG questions the validity of this 
assumption as there appears to be no clinical effectiveness evidence to confirm or refute this 
claim. Third, treatments received on disease progression in the dacarbazine arm and in the 
dabrafenib arm should be similar and typical of clinical practice. Aside from differences in types 
of the first systemic therapy received on disease progression noted above, 32 % of patients in 
the dacarbazine arm received two or more lines of treatment following disease progression 
(and a range of 12 treatments in total) whereas in the dabrafenib arm it was 19 % (and a range 
of 23 treatments in total). Therefore, from trial data made available by the company the ERG 
did not consider that all patients in the BREAK-3 [17] study received similar treatments at the 
time of disease progression or that patients in both groups received treatments that are 
routinely available in UK clinical practice. Furthermore, as part of its critique of the cost-
effectiveness evidence (see 3.2.2 below), the ERG found that patients who crossed over to 
 Page 11 of 27 
 
receive dabrafenib did not gain any significant benefit over the patients who did not crossover 
meaning the need to adjust for crossover was not in fact warranted.  
 
Regardless of whether there was a need to adjust OS for treatment crossover, the ERG is of the 
opinion that an ITC using RPSFTM adjusted estimates should constitute a sensitivity analysis 
rather than the primary analysis. Therefore, as noted above, the ERG requested the company 
also conduct the ITC with unadjusted OS from both BREAK-3 [17] and BRIM-3 [18] which 
suggested that dabrafenib and vemurafenib may be of equal clinical efficacy. However, the ERG 
was not convinced the results from the ITC were robust because three key assumptions did not 
hold. First, constant proportional hazards were required for both PFS and OS data within the 
BREAK-3 [17] trial (dabrafenib vs dacarbazine). Analyses conducted by the ERG indicated a 
significant deviation from constant HR between the trial arms for PFS (p<0.001, chi-squared 
test) but not for OS (p=0.91). Second, constant proportional hazards were also required for 
both PFS and OS data within the BRIM-3 [18] trial (vemurafenib vs dacarbazine). ERG analyses 
indicated significant deviations from this assumption for both outcomes (p<0.001 for PFS, 
p<0.001 for OS, chi-squared test). Finally, PFS and OS data for dacarbazine within the two trials 
should be broadly comparable and conform to a constant proportional hazard relationship. 
Comparison of dacarbazine PFS and OS data indicated that PFS hazard profiles were not 
significantly different (p=0.46); however constant proportion hazards were not supported for 
OS (p<0.001). 
 
Regarding safety, the ERG noted that no significant differences between dabrafenib and 
vemurafenib were reported for any of the types of AEs analysed in a separate report conducted 
on behalf of the company [28]. Dabrafenib was however reported to be associated with 
significantly fewer incidences of diarrhoea, nausea, and photosensitivity than vemurafenib. The 
incidence of all-grade and Grade 3 cutaneous SCC, keratoacanthomas and arthralgia were also 
reported to be higher with vemurafenib whereas pyrexia, hyperkeratosis and palmar-plantar 
erythrodysesthesia (PPE) syndrome were more common with dabrafenib.  
 
Data on HRQoL were limited in the company’s submission [11].  
 
3.1.2 Evidence Review Group Conclusions on the Submitted Clinical Evidence 
Based on current clinical practice, vemurafenib is a more appropriate comparator for 
dabrafenib then dacarbazine. Unfortunately, the ERG is also of the opinion that there is no 
robust evidence available to enable a credible comparison of the clinical effectiveness of 
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dabrafenib vs vemurafenib. This is because three key assumptions regarding constant 
proportional hazards required for the conduct of the ITC did not hold. While dabrafenib and 
vemurafenib have some AEs in common, there are notable differences between the two drugs 
for a number of AEs. Specifically, hyperproliferative skin toxicities (cutaneous SCC and 
keratoacanthomas), photosensitivity and arthralgia appear to be more common and more 
severe with vemurafenib whereas pyrexia, hyperkeratosis and PPE syndrome appear to be 
more common with dabrafenib. There are no comparative quality of life data for dabrafenib 
and vemurafenib. It is worth noting that photosensitivity, when discussed as part of the STA for 
vemurafenib, was described as not clinically important. However, during this appraisal clinicians 
identified it as a major limiting factor in terms of quality of life in the use of vemurafenib.  
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3.2 Cost effectiveness Evidence 
The company undertook a de novo economic evaluation of dabrafenib (intervention) compared 
with dacarbazine or vemurafenib (comparators) for the first-line treatment of patients with 
locally advanced or metastatic BRAF V600 mutation positive malignant melanoma. The 
economic model took an NHS perspective; the time horizon was 30 years; and costs and 
outcomes were discounted at 3.5 %. The model comprised three states (PFS, post-progression 
survival [PPS], and death) and used a cycle length of 1 week. All patients started in the PFS 
state. At the end of each cycle, patients remained in PFS, moved to PPS, or died. Death was an 
absorbing health state.  
 
Modelled PFS and OS distributions were segmented into two periods, the trial period and the 
projection period. For both the trial and projection periods, PFS estimates for dabrafenib and 
dacarbazine were derived from parametric survival distributions fitted to investigator-assessed 
PFS from BREAK-3 [17] (June 2012 data cut). Constant proportional hazards were used to model 
PFS for vemurafenib. During the trial period (from randomization until 1.8 years) the OS 
projection for dabrafenib was based on an independent parametric survival distribution fitted 
to individual patient data from BREAK-3 [17] (December 2012 data cut), the dabrafenib vs 
dacarbazine RPSFTM adjusted HR from BREAK-3 [17] was used to project dacarbazine OS and 
constant proportional hazards were the basis for modelling OS for vemurafenib. For the period 
from the end of the trial period out to 10-years, survival for patients receiving dabrafanib was 
based on a parametric survival curve fitted to American Joint Committee on Cancer (AJCC) 
registry data [8]. Constant proportional hazards (the same values as used in the trial period) 
were used to model survival for dacarbazine and vemurafenib. Beyond 10 years, survival was 
based on UK general population mortality data. 
 
Utility values incorporated into the model were those derived from BREAK-3 [17]. In the 
absence of equivalent data for patients receiving vemurafenib it was assumed that the HRQoL 
of these patients was the same as that for patients who received dabrafenib. Costs 
incorporated in the company's model included drug costs (calculated using a confidential 
discounted cost as agreed as part of the NHS PAS), dispensing costs for dabrafenib and 
vemurafenib, administration cost for dacarbazine, BRAF V600 mutation testing, anti-cancer 
therapy after the study, costs associated with health states and AEs and one-off costs for 
starting treatment and for death. The main sources of cost data used in the model were the 
NHS Reference Cost Schedule (12-13), the British National Formulary and the results of a cost-
of-illness study commissioned by the company (GSK data on file).  
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The company’s base-case incremental cost-effectiveness ratio (ICER) for dabrafenib vs 
dacarbazine for the first-line treatment of locally advanced or metastatic BRAF V600 mutation 
positive malignant melanoma was £60,980 per quality adjusted life year (QALY) gained and 
£44,088 per life year gained. The ICERs for dabrafenib vs vemurafinib were £11,046 per QALY 
gained and £7,522 per life-year gained. The company's probabilistic analysis showed that at a 
maximum acceptable ICER of £30,000 per QALY, dabrafenib would have a 6 % probability of 
being cost effective compared with dacarbazine and a 56 % probability compared with 
vemurafenib. The company also conducted a series of deterministic sensitivity analyses. For the 
comparison with dacarbazine, OS was the key driver of the cost-effectiveness results and the 
key driver for the comparison with vemurafenib was the PFS assumption (alternative survival 
functions for PFS were explored).  
 
3.2.1 Critique of Cost effectiveness Evidence and Interpretation 
The spreadsheet model submitted by the company was considered by the ERG to be more 
complex than would normally be considered necessary, or appropriate, for the relatively simple 
logical structure of a three-state transition model. As a consequence, the ERG struggled to trace 
the logic trails for normally straightforward aspects of such a model. Another difficulty with this 
structure is that it only allows results for a single regimen to be generated at a time. 
Incremental comparisons and incremental cost-effectiveness ratios (ICERs) can only be 
obtained by generating and saving costs and outcomes separately for each regimen, before 
they can be combined to give the final result. 
 
In the company’s model, the ERG noted that the majority of the estimated incremental QALYs 
arise from estimated life-years in post-progression survival (PPS) (62 % for dabrafenib vs 
dacarbazine, 93 % for dabrafenib vs vemurafenib). For dabrafenib vs dacarbazine nearly all of 
the incremental costs (99.3 %) are drug related costs that occur during PFS whereas for 
dabrafenib vs vemurafenib incremental costs are divided almost equally between PFS (44.1 %) 
and PPS (46.3 %). Thus the methods used to estimate PFS, OS and PPS, based on data from the 
BREAK-3 [17] trial, were considered central to determining the most reliable assessment of cost 
effectiveness by the ERG. The ERG highlighted that the importance of the large estimated 
values for PPS gain ascribed to dabrafenib becomes clear from the sensitivity of the company’s 
ICER to alternative assumptions: if only 50 % of the PPS gain in the company’s base case is 
considered realistic, the ICER increases by about 45 % to over £70,000 per QALY gained; if there 
 Page 15 of 27 
 
is no additional survival advantage from dabrafenib beyond disease progression, the ICER more 
than doubles to over £120,000 per QALY gained. 
 
The ERG therefore considered the three phases of the model and the assumptions underlying 
the modelling of these. First, modelling during the trial period (up to 1.8 years) requires the 
same three assumptions to hold as described for the ITC to produce valid results. As described 
above, the ERG did not consider this was the case. In addition, the reliability of the 
representation of dacarbazine is strongly affected by the efficacy of the assumptions made to 
support the use of the RPSFTM adjustment. Moreover, the ERG demonstrated that using trial 
data followed by an exponential extrapolation gave a better fit. Second, the company’s model 
assumes that a log-logistic parameterization of AJCC registry data [8] is appropriate for 
modelling survival from 1.8 to 10 years. However, no evidence to support the clinical or 
biological plausibility of this assumption was provided and furthermore, the ERG noted that the 
AJCC published data [8] relates specifically to a North American as opposed to UK population. 
During phase 3, the company’s model defaults to the use of background mortality rates based 
on UK life table statistics to represent the experience of all survivors from 10 to 30 years. The 
ERG noted that this implicitly assumes that long-term survivors are effectively cured of 
metastatic cancer, a very strong assumption for which no supporting objective evidence was 
provided by the company. The ERG expressed particular concern about the discontinuities in 
mortality rates that occurred between phase I and phase 3 (as shown in Figure 1). While such 
abrupt changes in mortality can occur in clinical trials, they are always the consequence of a 
significant disease or treatment event, such as the start or termination of treatment, or a 
serious alteration in a patient’s condition. The abrupt changes in mortality rates observed here, 
however, have no clinical explanation and only relate to convenient choices made for modelling 
purposes. However, the consequence of these choices is to bias the analysis in favour of 
dabrafenib and against the comparators, especially dacarbazine.  
 
Finally, the ERG noted that the company has used RPSFTM adjusted data as the basis for 
modelling OS. The ERG accepted that adjusting for crossover may appear to be a sensible 
measure, particularly where the treatment that is crossed over to is showing improved efficacy, 
as appears to be the case from an analysis of OS, PFS and ORR in BREAK-3 [17]. However, the 
ERG also argued that the assumption requires strong justification since it can radically alter the 
model estimates of cost effectiveness. In particular, the ERG noted, patients in the dacarbazine 
arm whose disease has progressed are unlikely to be in a similar physical condition (and 
therefore have similar survival prognosis) as those starting dabrafenib as first-line 
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chemotherapy. Hence while treatment crossover may have some efficacy, it is not certain that 
the recipients will receive 100 % of the efficacy experienced in first-line therapy since those 
patients suffering early progression are likely to be those with the least propensity to benefit 
from further treatment. Therefore the ERG requested an analysis of PPS comparing 37 
dacarbazine treated patients (69 %) who received subsequent dabrafenib with the 17 patients 
(31 %) who did not. Despite this being a non-randomized comparison, similar proportions died 
(70 % and 71 % respectively) and remained in ongoing follow-up at data-cut (24 % and 24 % 
respectively). The time from disease progression in terms of median (50 % survival), first 
quartile (75 % survival) and third quartile (25 % survival) are shown in Figure 2 together with 
confidence intervals. It is apparent that these data offer no convincing evidence of any 
significant survival difference, and therefore the null hypothesis (that there is no crossover 
effect favouring dabrafenib) cannot be rejected. This is particularly important since the use of 
the RPSFTM adjusted survival data from the BREAK-3 [17] trial establishes a large survival 
difference at the end of the trial data (after 1.8 years). The subsequent use of reduced mortality 
rates in phases 2 and 3 has the effect of extending the duration of this benefit. The result is that 
PPS gains are elongated and the ICER per QALY gained for dabrafenib compared with 
dacarbazine is substantially reduced. 
 
The ERG carried out an analysis to determine the effect of censoring bias. This analysis was 
done to inform the choice of the most suitable parametric function with which to model 
BREAK-3 [17] PFS data in order to allow reliable long-term projection of PFS trends. The ERG 
noted that, for both dabrafenib and dacarbazine, it appears that there is a short period 
(between 8 and 12 weeks) free of events, followed by a period of high event risk modulated by 
a regular pattern related to the regular protocol-determined patient assessments. Finally, in 
both trial arms the cumulative hazard trend settles to a steady near-linear pattern. The ERG 
therefore concluded that the most appropriate method of representing lifetime PFS trends was 
to use the ‘area under the curve’ (AUC) approach to capture PFS in the early variable segment, 
and then fit a simple linear cumulative hazard trend, equivalent to an exponential projective 
function for the latter period.  
 
 
The results are shown in Figure 3 and Figure 4, and compared with both the trial Kaplan-Meier 
data and the company’s log-normal models. It is evident that the company’s approach tends to 
over-estimate the long-term hazard rate (i.e. under-estimate PFS) in both the dabrafenib arm 
and the dacarbazine arm. This is a result of using the whole data set (including the early 
 Page 17 of 27 
 
variable phase) for model calibration and the adoption of a common constant proportional 
hazards assumption. 
 
The ERG’s re-analysis of PFS data resulted in an additional 7 to 8 days of PFS gain from use of 
dabrafenib. Using the ERG PFS estimates in the company’s model results in a small increase in 
the incremental QALYs per patient (+0.16 %). There is, however, a much larger increase in the 
incremental cost per patient (+6.32 %). This is mainly due to additional days of treatment with 
dabrafenib. The ERG’s alternative projection of OS reduced the estimated OS gain by almost 70 
%. Combining all of the ERG’s changes results in an ICER of £112,727 per QALY gained for 
dabrafenib vs dacarbazine. 
 
The ERG did not conduct exploratory analyses to examine the ICER for dabrafenib vs 
vemurafenib, because the ERG did not believe the results from the ITC were credible for the 
reasons outlined above. 
 
3.2.2 Evidence Review Group Conclusions on the Submitted Cost effectiveness Evidence 
The company has submitted a complex decision model involving important assumptions which 
the ERG considers lack reliable evidential support. The three-phase survival model generates 
unexpected and unjustifiable sudden changes in mortality rates which serve only to artificially 
extend expected patient survival times and thereby exaggerates the apparent post-treatment 
survival benefit attributed to dabrafenib. Crossover analyses employed by the company are not 
supported by objective evidence that such crossover has any measurable effect on survival 
outcomes. Nor are crossover analyses supported by evidence that patients electing for 
crossover at disease progression to receive dabrafenib are in a similar condition, and therefore 
have an equivalent propensity to benefit, to those receiving dabrafenib at randomization. 
Crossover analyses should therefore be considered speculative. Applying the latest OS data 
from BREAK-3 [17] to a less complex model structure based solely on survival data from this 
trial reduces the net survival gain by almost 70 %. Applying all additional ERG amendments 
increases the estimated ICER for dabrafenib compared with dacarbazine from £60,980 to 
£112,727 per QALY gained. The ERG does not believe assumptions about constant proportional 
hazards both within and between the two trials used to derive an ITC of dabrafenib to 
vemurafenib are valid. Therefore results of the comparison of dabrafenib to vemurafenib 
should not be considered meaningful or reliable. 
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4 National Institute for Health and Care Excellence Guidance 
The AC agreed that the appropriate comparator for this appraisal was vemurafenib. It 
acknowledged the concerns of the ERG related to the lack of direct evidence to compare the 
effectiveness of dabrafenib and vemurafenib, the significant limitations of the ITC provided by 
the company and the numerous uncertainties related to the assumptions related to survival in 
the economic model provided by the company.  
 
In addition to the evidence presented by the company and critiqued by the ERG, the AC took 
into account the views of a patient expert and clinical specialist. The patient expert highlighted 
that metastatic melanoma can be associated with severe and debilitating symptoms and 
dabrafenib may sometimes have very rapid therapeutic effects such as improving poor 
performance status and slowing down the progression of high volume disease, even in those 
who are severely ill or bed-ridden. The clinical specialist stated that in clinical practice, the 
effectiveness of dabrafenib and vemurafenib were not considered to differ. Hence the choice 
between the two treatments would be largely based on their adverse reaction profiles. The 
clinical specialist explained that compared to vemurafenib there were much lower rates of 
photosensitivity (which may be a major problem for some patients) but higher rates of non-
specific fever.  
 
With regard to possible differences between the key trials, the AC also heard from the clinical 
specialist that although LDH level is one of many measures of disease severity used in clinical 
practice, it was not a marker of disease prognosis that could be relied on in isolation. Taking 
into account the evidence also presented by the company, the AC concluded that compared 
with dacarbazine, dabrafenib significantly improved PFS and ‘probably improved’ OS [29], 
noting that BRIM-3 [18] was a large trial and could show an OS benefit with vemurafenib, 
whereas BREAK-3 [17] was a smaller trial and it would be more difficult to demonstrate a 
statistically significant OS benefit with dabrafenib. The AC was therefore unable to draw firm 
conclusion about the magnitude of overall survival benefit. In spite of limitations in the data 
comparing dabrafenib to vemurafenib, the AC took the view that the two drugs were ‘likely’ of 
similar clinical effectiveness and since the overall costs were similar, the use of dabrafenib 
should be recommended in this patient population [29]. The AC therefore reached the 
following decision: ‘Dabrafenib is recommended, within its marketing authorisation, as an 
option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if 
the company provides dabrafenib with the discount agreed in the patient access scheme’ [29]. 
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5 Conclusion 
A clinical benefit of dabrafenib vs dacarbazine in terms of PFS has been demonstrated from 
BREAK-3 [17]. Significant benefits of vemurafenib vs dacarbazine in terms of PFS and OS have 
been demonstrated in BRIM-3 [18]. Vemurafenib is now the standard of care in clinical practice 
and hence it was important to compare dabrafenib to vemurafenib. In the absence of direct 
head-to-head evidence of these two drugs, the company conducted an ITC. The ERG noted key 
assumptions underpinning the conduct of the ITC did not hold and therefore put in question 
the validity of the clinical and cost effectiveness evidence derived from the ITC. Furthermore, 
with regard to cost effectiveness, the ERG noted the model suggested extensive PPS 
unsubstantiated by the existing data, clinical experience or even logical thought.  
 
The AC acknowledged the limitations with the evidence base highlighted by the ERG. However, 
it nevertheless concluded: ‘that there was no clear evidence that dabrafenib and vemurafenib 
differed in clinical effectiveness and that it would not be unreasonable to assume that they have 
similar effect’ [29]. Furthermore: ‘the overall costs were not different in the economic analysis … 
[and so] any difference in the cost effectiveness would be small and would fall within the range 
considered to be a cost effective use of NHS resources’ [29]. Hence, the use of dabrafenib was 
recommended for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. 
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 Tables and figures 
 
Table 1: Results of individual trials and inputs for the direct and indirect treatment comparisons 
Outcome 
BREAK-3 [17]  
PFS data-cut: June 2012 
OS data-cut: December 2012 
BRIM-3 [18] 
PFS and OS data-cut: February 2012 
 
Dabrafenib 
(N=187) 
Dacarbazine 
(N =63) 
Vemurafenib 
(n=337) 
Dacarbazine 
(N=338)  
Investigator assessed 
median PFS months (95 % 
CI)  
6.9 (5.2 to 9.0) 2.7 (1.5 to 3.2) 6.9 (6.1 to 7.0) 1.6 (1.6 to 2.1)  
ITT PFS HR (95 % CI); p-
value 
0.37 (0.24 to 0.58); p<0.0001 0.38 (0.32 to 0.46); p<0·0001 
Median OS months (95 % 
CI) 
 
18.2 (16.6 to NR) 15.6 (12.7 to NR) 
 
13.6 (12.0 to 15.2) 10.3 (9.1 to 12.8) 
Unadjusted OS HR (95 % 
CI) 
0.76 (0.49 to 1.18)a 0.76 (0.63 to 0.93)a 
RPSFTM adjusted HR (95 
% CI) 
0.55 (0.21 to 1.43)b 0.64 (0.53 to 0.78)b 
ORR % (95 % CI) 59 (51.4 to 66.0) 24 (14.0 to 36.2) 57c 8.6c 
This table is adapted from Table 8 of Fleeman et al [16]
 
(Crown copyright)  
 
CI confidence interval, HR hazard ratio, ITT intention to treat, ORR overall response rate, OS overall survival, PFS progression-free 
survival, RPSFTM Rank Preserving Structural Failure Time Model 
 
a Data input into the company’s modified ITC at the request of the ERG  
b Data input into the company’s original ITC 
c Only limited data for BRIM-3 was reported in the company’s submission (ORR % for vemurafenib arm reported in the text only 
with no CIs), the data for dacarbazine are therefore taken from the published paper for BRIM-3 [18]; it should also be noted that the 
data for BRIM-3 are confirmed by independent review whereas in BREAK-3, the investigator assessed ORR are reported  
 
 
Table 2: Results of indirect treatment comparison  
Outcome Treatment Control HR 95 % CI 
Lower Upper 
PFS Dabrafenib Vemurafenib 0.97 0.59 1.60 
RPSFTM 
adjusted OS 
Dabrafenib Vemurafenib 0.86 0.32 2.29 
Unadjusted 
OS 
Dabrafenib Vemurafenib 1.00 0.62 1.62 
This table is adapted from Table 10 and Table 11 of Fleeman et al [16]
 
(Crown copyright)  
CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival, RPSFTM Rank Preserving Structural 
Failure Time Model 
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Table 3: Type of first systemic therapy received on disease progression in BREAK-3  
Sytemic therapy Dabrafenib Dacarbazine 
Dabrafenib 37 (59 %)* 38 (20 %) 
Ipilimumab 2 (3 %) 25 (13 %) 
Dacarbazine 2 (3 %) 16 (9 %) 
Vemurafenib 6 (10 %) 9 (5 %) 
Fotemustine 1 (2 %) 4 (2 %) 
Lenvatinib mesilate 0 4 (2 %) 
Carboplatin/paclitaxel 0 3 (2 %) 
Interleukin-2 0 2 (1 %) 
Temozolomide 1 (2 %) 1 (<1 %) 
Mitogen-activated protein / extracellular signal-regulated kinase (nos) 0 1 (<1 %) 
Pembrolizumab 0 1 (<1 %) 
This table is adapted from data presented by the company as part of its factual error check of the ERG report (Crown copyright)  
* 36 (57 %) of patients were considered to have crossed-over by the company 
 
 
 
 
AJCC American Joint Committee on Cancer, HR hazard ratio, ITC indirect treatment comparison, RPSFTM Rank preserving 
structural time failure model, UK United Kingdom 
Figure 1 Mortality rates in the company’s base case analysis 
This figure is taken from Figure 5 of Fleeman et al [16]
 
(Crown copyright)  
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Figure 2 Post-progression survival comparing dacarbazine patients who did and did not 
crossover to dabrafenib on disease progression 
This figure is taken from Figure 6 of Fleeman et al [16]
 
(Crown copyright)  
 
 
Figure 3 BREAK-3 cumulative hazard Kaplan-Meier PFS  data, ERG long-term linear trends 
and the company’s log-normal models 
This figure is taken from Figure 14 of Fleeman et al [16]
 
(Crown copyright)  
ERG evidence review group, PFS progression-free survival 
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Figure 4 BREAK-3 Kaplan-Meier PFS data, ERG long-term exponential models and the 
company’s log-normal models 
This figure is taken from Figure 15 of Fleeman et al [16]
 
(Crown copyright)  
ERG evidence review group, PFS progression-free survival 
 
 
 
 
 
 
